Clin Mol Hepatol.
2021 Apr;27(2):273-277. 10.3350/cmh.2021.0019.
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
- Affiliations
-
- 1Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China
- 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
- 3Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
- KMID: 2514767
- DOI: http://doi.org/10.3350/cmh.2021.0019
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?
- Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
- Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
- Natural History and Treatment Indications of Chronic Hepatitis B
- PAGE-B with Moderate HBV DNA Levels Predicts Risk of Hepatocellular Carcinoma among Patients at Phase Change from Immuno-tolerant Phase to Immune-active Phase in HBeAg-Positive Chronic Hepatitis B
